NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

Vertex and CRISPR Therapeutics started submissions of exa-cel in sickle cell disease and beta thalassemia in November 2022. The regulatory progress has moved a bit faster outside the U.S., as the European Medicines Agency and U.K. authorities have already validated the filings. In the U.S., Vertex expects to complete a rolling submission by the end of March, CEO Reshma Kewalramani said on the call.

https://www.fiercepharma.com/marketing/vertex-teases-launch-plan-first-crispr-gene-editing-therapy-ahead-fda-decision

NWBO isn't the only novel medicine that appears to be progressing faster with the MHRA. Things have changed post breexit.